Literature DB >> 6498841

Establishment and characterization of human colorectal cancer cell lines.

J A McBain, J L Weese, L F Meisner, W H Wolberg, J K Willson.   

Abstract

A protocol for establishment of human colorectal carcinoma cell lines from fresh surgically removed tissues is described. Twelve human colorectal carcinoma cell lines were established from 6 of 18 primary cancers and four of four metastases. Cell lines from concurrent primary tumors and metastases were established from two individual patients. Two primary cancers gave rise to multiple cell lines with differing biological characteristics. Factors contributing to our success appear to be differential selection on the basis of substrate adherence and the timing of passage. The protocol avoids the use of feeder layers or passage through athymic mice. The established cell lines exhibit a range of karyotypes, morphologies, and growth characteristics.

Entities:  

Mesh:

Year:  1984        PMID: 6498841

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Biological features and chemosensitivity of human colorectal cancer xenografted in nude mice.

Authors:  K Yamada
Journal:  Gastroenterol Jpn       Date:  1987-10

2.  Kinetics of carcinoembryonic antigen and carbohydrate antigen 19-9 production in a human pancreatic cancer cell line (SUIT-2).

Authors:  T Iwamura; T Katsuki
Journal:  Gastroenterol Jpn       Date:  1987-10

3.  TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.

Authors:  Shinako Araki; Jacob A Eitel; Christopher N Batuello; Khadijeh Bijangi-Vishehsaraei; Xian-Jin Xie; David Danielpour; Karen E Pollok; David A Boothman; Lindsey D Mayo
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

4.  Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.

Authors:  D C Bicknell; A Rowan; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

Review 5.  Shaping future strategies for the pharmacological control of tumor cell metastases.

Authors:  R G Greig; D L Trainer
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

6.  Establishment and characterization of a bona fide Barrett esophagus-associated adenocarcinoma cell line.

Authors:  Hector Alvarez; Jan-Bart M Koorstra; Seung-Mo Hong; Jurjen J Boonstra; Winand N M Dinjens; Arlene A Foratiere; Tsung-Teh Wu; Elizabeth Montgomery; James R Eshleman; Anirban Maitra
Journal:  Cancer Biol Ther       Date:  2008-11-04       Impact factor: 4.742

7.  Highly lytic CD8+, alpha beta T-cell receptor cytotoxic T cells with major histocompatibility complex (MHC) class I antigen-directed cytotoxicity in beta 2-microglobulin, MHC class I-deficient mice.

Authors:  S Apasov; M Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

8.  Personalized chemotherapy profiling using cancer cell lines from selectable mice.

Authors:  Hirohiko Kamiyama; Sherri Rauenzahn; Joong Sup Shim; Collins A Karikari; Georg Feldmann; Li Hua; Mihoko Kamiyama; F William Schuler; Ming-Tseh Lin; Robert M Beaty; Balasubramanyam Karanam; Hong Liang; Michael E Mullendore; Guanglan Mo; Manuel Hidalgo; Elizabeth Jaffee; Ralph H Hruban; H A Jinnah; Richard B S Roden; Antonio Jimeno; Jun O Liu; Anirban Maitra; James R Eshleman
Journal:  Clin Cancer Res       Date:  2013-01-22       Impact factor: 12.531

9.  Establishment of primary cell cultures: experiences with 155 cell strains.

Authors:  M Dietel; H Arps; D Gerding; M Trapp; A Niendorf
Journal:  Klin Wochenschr       Date:  1987-06-01

10.  Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness.

Authors:  L-B Weiswald; S Richon; P Validire; M Briffod; R Lai-Kuen; F P Cordelières; F Bertrand; D Dargere; G Massonnet; E Marangoni; B Gayet; M Pocard; I Bieche; M-F Poupon; D Bellet; V Dangles-Marie
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.